ABSTRACT Monoclonal antibody 9.2.27 (mAb 9.2.27) directed to a chondroitin sulfate proteoglycan on human melanoma cells was able to suppress tumor growth in athymic (nu/nu) mice more effectively when bound with polyethylene glycol to murine effector cells than when injected alone. These "armed" effector cells also proved more effective than the monoclonal antibody in eliciting antibody-dependent cellular cytotoxicity against human melanoma target cells in vitro.
We have previously described the production of hybridomas secreting a monoclonal antibody 9.2.27 (mAb 9.2.27) which reacts with an antigenic structure expressed preferentially on the surface of human melanoma cells (1) . In a series of additional experiments employing pulse-chase biosynthetic studies as well as biochemical and topographical analyses, we clearly identified the antigen recognized by mAb 9.2.27 as the core glycoprotein for a chondroitin sulfate proteoglycan expressed in the pericellular matrix of melanoma cells (2) . In additional studies, we were able to show that mAb 9.2.27 per se could suppress the growth of human melanoma tumors in nude mice to an extent that was equally as great as when the same antibody was conjugated with diphtheria toxin A chain (3) .
Several investigators have reported that monoclonal antibodies directed against malignant melanoma can mediate antibody-dependent cellular cytotoxicity (ADCC) in vitro (4, 5) . Other studies suggested that "arming" effector cells with antibodies before incubation with target cells provides an alternative way to achieve specific cell killing in vitro by a mechanism termed directed ADCC (6, 7) . These studies made use of anti-trinitrophenyl (TNP) "armed" effector cells and TNPcoated target cells or effectors armed with antibody to human chorionic gonadotropin and IEG-3 choriocarcinoma target cells. It was also demonstrated that this directed ADCC reaction was not inhibited by immune complexes as is the classical ADCC (6, 7) .
The aim of our study was twofold: First, we wished to determine whether murine effector cells armed with a highly specific monoclonal antibody (mAb 9.2.27) against a well-defined antigen expressed on the surface of human melanoma cells are able to specifically kill these cells in vitro by a directed ADCC reaction. Second, we wanted to assess whether these antibodycoated or armed effector cells are able to achieve a more effective suppression of human melanoma tumor growth in nude mice than that obtained previously by injection of the mAb 9.2.27 per se (3) .
MATERIALS AND METHODS
Tumor Cell Lines. The M21 human melanoma cell line utilized for these studies was originally derived from a secondary metastasis of human melanoma by Donald Morton and colleagues at U.C.L.A. (8) . In several experiments, we also used the M14 human melanoma cell line (9) (12) . The statistical significance of differences in mean tumor volume of each group was evaluated by Student's t test.
Fluorescein Labeling of Antibody. IgG in phosphate-buffered saline (1 mg/ml) was adjusted to pH 9.0 with 0.1 ml of a 0.5 M sodium borate buffer, pH 9.0, and then admixed with 100 ,ug of fluorescein isothiocyanate dissolved in 10 ,ul of N,Ndimethylformamide (Sigma) . After Fig. 4 indicate that the suppression of melanoma tumor growth by the effector cell-antibody complex is, even at this low concentration, similar to that observed with the higher dose therapy. Tumors of animals in group I became necrotic at day 15 and remained so until day 32-i. e., there was no observable increase in tumor volume. The inhibition of tumor growth in group I compared to that of untreated animals (group IV) was 93% at day 32. Inhibition of tumor growth was observed in group II (effector cells plus polyethylene glycol) and group III (mAb 9.2.27 alone) at 59% and 67%, respective to untreated control animals (group IV). While the inhibitory effect of mAb 9.2.27 alone agrees with the results obtained in a previous study (3), the inhibition of tumor growth achieved by polyethylene glycol-treated effector cells suggests that polyethylene glycol may activate the cytotoxic capacity of such cells. However, the mean volume of tumors in control groups II and III remained 5-to 6-fold greater than that of animals in group I, which received therapy with antibody bound to effector cells. The mean melanoma tumor volume in animals treated with armed effectors was significantly smaller than that of mice treated with mAb 9.2.27 IgG alone (P < 0.01), with effector cells only (P < 0.01), and untreated animals (P < 0.001).
In order to assess whether an immunity against a second tumor challenge developed, we reinjected 7.5 X 106 M21 cells subcutaneously into four mice in each treatment group 7 days after the last therapeutic injection. Within 1 week, not only all control animals but also all mice in the three therapy groups showed the appearance of a second tumor, suggesting that no prolonged immunity developed. 
DISCUSSION
The results of our experiments clearly indicate that the directed ADCC was at least twice as effective as the classical ADCC reaction in inducing specific tumor cell killing as measured by a 5"Cr release assay. In addition, only the directed ADCC reaction showed a statistically highly significant reactivity (P < 0.001) compared to that of NK.cells. The relatively small (=15%) specific release of 51Cr observed in the classical ADCC reaction (target-to-effector ratio = 1:100) is not unusual because earlier studies by other investigators (4, 5) already indicated that, even at prolonged incubation times, a variety of monoclonal antibodies directed against human melanoma cells did not induce a specific release of 5"Cr greater than 15% at this same targetto-effector ratio. The relatively low efficiency of ADCC in melanoma is not surprising because it is known that cells of solid human tumors are far more resistant to cell-mediated cytotoxicity than are lymphoblastoid cells (13 Although the injection of effector cells treated only with polyethylene glycol resultedin some suppression of melanoma tumor growth, it was far smaller than that achieved by effector cells conjugated with mAb 9.2.27. This effect may have been induced by cytotoxic T cells because it was initially observed 10 days after the first injection, whereas antibody alone and antibody-effector cell conjugates showed an earlier effect on tumor growth. This observation may be explained by the fact that cytotoxic T cells are known to require several days for a primary response, whereas K cells and macrophages are able to kill tumor cells within hours (16) . Treatment of effector cells with polyethylene glycol may actually have increased their ability to kill tumor cells, because preliminary experiments indicated a diminished effect on tumor growth suppression when effector cells not treated with polyethylene glycol were injected into tumor-bearing mice. The greater efficacy of the effector cell-antibody complex may be explained by the fact that the IgG fixed onto the surface of these cells by polyethylene glycol is less likely to dissociate in vivo and thus to bind to immune complexes or other serum blocking factors, both of which have been implicated in lowering the efficacy of tumor immunotherapy (17) (18) (19) .
On the basis of a number of experiments, several hypotheses have been advanced concerning the mechanism(s) by which monoclonal antibodies are believed to effect the killing of tumor cells in vivo. Thus, Herlyn and Koprowski have demonstrated that growth suppression of human colorectal tumors in nude mice is mediated by macrophages with specific Fc receptors for antibodies of the IgG2a isotype (20) . These investigators have also shown that complement is not required for this tumor cell destruction. The mAb 9.2.27 used in our experiments certainly satisfies these requirements because it is of IgG2a isotype and does not fix complement (1) .
Although several investigators (21, 22) have shown that the interaction between macrophages and immunoglobulins is important for tumor killing, other cells, 'such as K cells, may also be involved in this process because they are known to kill malignant cells in vivo. In this regard, a common surface component of both macrophages and K cells are Fc receptors (16) . Because the effector cells used in our experiments were unfractionated, we cannot identify the relevant cell types involved in this directed ADCC. At this time, we are unable to distinguish among possible mechanisms by which effector cells armed with mAb 9.2.27 IgG effect destruction of human melanoma tumors in nude mice. However, it appears likely that Fc receptors on macrophages, lymphocytes, or a combination of these and other factors are required for the tumoricidal effects we observed. Further studies are required to formulate a viable hypothesis for this potentially important process of tumor destruction.
To the best of our knowledge, no clinical application of polyethylene glycol-mediated arming of effector cells with monoclonal antibodies has been made. Sears et aL (23) have admin-istered monoclonal antibodies together with a patient's monocytes in earlier trials of immunotherapy for colorectal cancer. No extraordinary effect was observed; however, the stability of a nonpolyethylene glycol-mediated formation of monoclonal antibody-effector cell complex is questionable and thus this concept remains to be tested under optimal conditions. Nevertheless, one can visualize that in patients with relatively low tumor load-e.g, after surgical resection, the patient's own effector cells armed with a specific monoclonal antibody or even a panel of such reagents could provide useful therapy or prophylaxis. For example, suitable effector cells could be collected at a time when the patient is still immunocompetent. Such cells could then be frozen.(in dimethyl sulfoxide) until needed to be complexed with suitably specific monoclonal antibodies just prior to injection while using the patient's own serum to remove excess dimethyl sulfoxide and polyethylene glycol. Conceivably, such armed effector cells may under certain circumstances prove useful in preventing or at least slowing down recurrence of metastatic tumor growth.
